

In the Claims

Please amend the claims as follows (where insertions are underlined, and deletions are placed in brackets):

Sub E2  
DJ  
1. (Thrice amended) Method to kill breast cancer cells or other carcinoma cells expressing [the same] target antigens in a cell population selected from the group consisting of cells comprising nucleated cells in peripheral blood and bone marrow cells comprising CD-34<sup>+</sup> cells selected from the above nucleated cells, wherein the cell population is exposed to a combination of two immunotoxins, wherein each immunotoxin is composed of a conjugate between an antibody and a cell toxin, antigen binding antibody fragments and [active] toxin fragments, or recombinantly produced antibodies, toxins, immunotoxins or fragments thereof, wherein the antibodies are directed to epitopes on the antigen EGP2 expressed by the gene GA733-2 and to epitopes on the antigen expressed by the MUC1 gene and the toxin is Pseudomonas exotoxin A.

[Please add new claims <sup>14-24</sup> 15-25 as follows:]

Rule 1.126  
15. (New) A method for killing malignant cells in a cell population, the method comprising

obtaining the population of cells *ex vivo* that contains the malignant cells;

Sub E6  
DJ  
contacting the population of cells with at least two immunotoxins, wherein a first immunotoxin comprises a PE molecule conjugated to an antibody or an antibody fragment capable of binding an EGP2 antigen which is expressed by a GA733-2 gene and a second immunotoxin comprising a PE molecule conjugated to an antibody or an antibody fragment capable of binding an antigen encoded by the MUC1, MUC2, or MUC3 gene.

16. (New) The method according to claim 15, wherein the first immunotoxin comprises a PE molecule conjugated to a MOC31 antibody or an antigen-binding

antibody fragment thereof, and the second immunotoxin comprises a PE molecule conjugated to a 595A6 antibody or an antigen-binding antibody fragment thereof.

Sub E6 16  
Rule 1.124  
17. (New) The method according to claim 15, wherein the cell population is obtained *ex vivo* from a cancer patient.

18. (New) The method according to claim 17, wherein the cell population comprises peripheral blood cells or bone marrow cells.

19. (New) The method according to claim 18, wherein the cell population comprises CD34+ cells

20. (New) The method according to claim 19, wherein the cell population is enriched or positively selected for CD34+ cells.

21. (New) The method according to claim 1 wherein treatment of the cell population with the two or more immunotoxins causes low toxicity to CD34+ cells in the population.

22. (New) A method for killing malignant cells in a patient, the method comprising

administering to the patient a therapeutically effective amount of at least two immunotoxins, wherein a first immunotoxin comprises a PE molecule conjugated to an antibody or an antibody fragment capable of binding an EGP2 antigen which is expressed by a GA733-2 gene and a second immunotoxin comprises a PE molecule conjugated to an antibody or an antibody fragment capable of binding an antigen encoded by the MUC1, MUC2, or MUC3 genes.

23. (New) The method according to claim 22, wherein the patient is a cancer patient.

24. (New) The method according to claim 22, wherein the malignant cells are carcinomas.